K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting compone...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hofmann, Irmgard, Weiss, Andreas, Elain, Gaelle, Schwaederle, Maria, Sterker, Dario, Romanet, Vincent, Schmelzle, Tobias, Lai, Albert, Brachmann, Saskia M., Bentires-Alj, Mohamed, Roberts, Thomas M., Sellers, William R., Hofmann, Francesco, Maira, Sauveur-Michel
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2012
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432074/
https://ncbi.nlm.nih.gov/pubmed/22952903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044146
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires